The company's clinician-first, deep learning neurodiagnostic solutions allow healthcare professionals such as neuroradiologists, radiation oncologists, neurologists, neurosurgeons, and neuroscience researchers to analyze MRI sequences and provide an automated response assessment about tumors that are irregular in shape, such as glioblastoma. NeoSoma's patented FDA cleared technology integrates seamlessly between healthcare professionals and allows the integration of non-imaging information for more precise analysis of patient data. Led by experienced practicing physicians and software veterans, NeoSoma's approach puts the patient and the physician first, resulting in the best positive impact on patients' health and the community.